Meridian Bioscience To Buy Molecular Reagents Manufacturer Bioline Group

Bioline manufactures and distributes specialised molecular biology reagents for the life science research, biotech, pharmaceutical, and commercial diagnostic markets in Germany, Australia, and the US.

Meridian said that, through the acquisition and internal development of advanced enabling technologies, it continues to expand its life science business to support and service researchers, diagnostic test manufacturers, as well as pharmaceutical and biotechnology companies.

Following the acquisition, the Bioline management team is expected to remain in place and continue to operate the Bioline group of companies.

Richard Eberly, executive vice president and president of Meridian Life Science, said: “Bioline will provide a rapidly expanding portfolio of specialised molecular biology reagents that enable the development of genomic tests utilized by researchers, clinical diagnostic laboratories, diagnostic test manufacturers, and biotechnology companies.

“Bioline will also add key global operations and direct sales capabilities in the UK, Germany, and Australia to complement Meridian’s strong US capabilities.”

Jack Kraeutler, CEO of Meridian Bioscience, said: “As we have indicated recently, it is our intention to continue to seek acquisitions and alliances that make sense for the Meridian customer and shareholder. Excluding transaction costs, we expect that this acquisition will be accretive in fiscal 2011.”

Marco Calzavara, founder and CEO of Bioline, said: “Bioline’s expertise and solid manufacturing capability coupled with an extensive Sales and International distribution network, will complement and enhance the Meridian Group.”